TC Biopharm (TCBP) Competitors $0.66 +0.00 (+0.15%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrends TCBP vs. ADXS, EVFM, NMTR, HSTO, PXMD, PTEIQ, SRNE, PKBO, BDRX, and NEXIShould you be buying TC Biopharm stock or one of its competitors? The main competitors of TC Biopharm include Ayala Pharmaceuticals (ADXS), Evofem Biosciences (EVFM), 9 Meters Biopharma (NMTR), Histogen (HSTO), PaxMedica (PXMD), PolarityTE (PTEIQ), Sorrento Therapeutics (SRNE), Peak Bio (PKBO), Biodexa Pharmaceuticals (BDRX), and NexImmune (NEXI). These companies are all part of the "pharmaceutical products" industry. TC Biopharm vs. Ayala Pharmaceuticals Evofem Biosciences 9 Meters Biopharma Histogen PaxMedica PolarityTE Sorrento Therapeutics Peak Bio Biodexa Pharmaceuticals NexImmune Ayala Pharmaceuticals (NASDAQ:ADXS) and TC Biopharm (NASDAQ:TCBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment. Do analysts prefer ADXS or TCBP? TC Biopharm has a consensus price target of $3.00, suggesting a potential upside of 354.55%. Given TC Biopharm's stronger consensus rating and higher possible upside, analysts plainly believe TC Biopharm is more favorable than Ayala Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00TC Biopharm 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ADXS or TCBP? In the previous week, TC Biopharm had 3 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for TC Biopharm and 0 mentions for Ayala Pharmaceuticals. TC Biopharm's average media sentiment score of 0.47 beat Ayala Pharmaceuticals' score of 0.00 indicating that TC Biopharm is being referred to more favorably in the news media. Company Overall Sentiment Ayala Pharmaceuticals Neutral TC Biopharm Neutral Do institutionals and insiders hold more shares of ADXS or TCBP? 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 16.3% of TC Biopharm shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 15.4% of TC Biopharm shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher valuation & earnings, ADXS or TCBP? TC Biopharm has higher revenue and earnings than Ayala Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAyala Pharmaceuticals$3.24M0.36-$48.07M-$7.980.00TC Biopharm$4.76M0.07-$7.35MN/AN/A Which has more risk & volatility, ADXS or TCBP? Ayala Pharmaceuticals has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, TC Biopharm has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500. Does the MarketBeat Community prefer ADXS or TCBP? TC Biopharm received 2 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 66.67% of users gave TC Biopharm an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAyala PharmaceuticalsOutperform VotesNo VotesUnderperform Votes66100.00% TC BiopharmOutperform Votes266.67% Underperform Votes133.33% Is ADXS or TCBP more profitable? Company Net Margins Return on Equity Return on Assets Ayala PharmaceuticalsN/A N/A N/A TC Biopharm N/A N/A N/A SummaryTC Biopharm beats Ayala Pharmaceuticals on 11 of the 13 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get TC Biopharm News Delivered to You Automatically Sign up to receive the latest news and ratings for TCBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCBP vs. The Competition Export to ExcelMetricTC BiopharmBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$348,000.00$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E RatioN/A46.7390.1317.19Price / Sales0.07415.011,116.25117.01Price / CashN/A182.1043.1037.85Price / Book0.023.894.784.78Net Income-$7.35M-$42.21M$120.31M$225.60M7 Day Performance24.76%-2.15%-1.92%-1.23%1 Month Performance5.79%1.73%13.65%0.46%1 Year Performance-97.31%16.36%28.34%15.24% TC Biopharm Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCBPTC Biopharm2.9794 of 5 stars$0.66+0.2%$3.00+354.5%-97.4%$348,000.00$4.76M0.0041News CoverageGap DownADXSAyala PharmaceuticalsN/A$0.03flatN/A-95.7%$1.15M$10,000.000.0020Analyst ForecastGap UpEVFMEvofem BiosciencesN/A$0.01-1.0%N/A-83.9%$1.09M$11.39M-0.02120Gap UpNMTR9 Meters BiopharmaN/A$0.07-43.0%N/AN/A$1.04MN/A-0.0220High Trading VolumeHSTOHistogenN/A$0.22+975.0%N/A-91.3%$918,000.00$19,000.00-0.017Gap UpPXMDPaxMedicaN/A$0.08+12.4%N/A-90.3%$890,000.00N/A0.002Gap UpPTEIQPolarityTEN/A$0.08flatN/A+18.1%$615,000.00$810,000.00-0.0460High Trading VolumeSRNESorrento TherapeuticsN/A$0.00-26.7%N/A-96.5%$606,000.00$62.84M0.00800Analyst ForecastGap DownPKBOPeak BioN/A$0.02-67.9%N/A-81.3%$520,000.00$370,000.00-0.143Gap DownHigh Trading VolumeBDRXBiodexa Pharmaceuticals1.5809 of 5 stars$4.28+1.9%$200.00+4,572.9%N/A$509,000.00$83,000.000.0021NEXINexImmuneN/A$0.30+30.4%N/A-89.7%$418,000.00N/A-0.016 Related Companies and Tools Related Companies Ayala Pharmaceuticals Alternatives Evofem Biosciences Alternatives 9 Meters Biopharma Alternatives Histogen Alternatives PaxMedica Alternatives PolarityTE Alternatives Sorrento Therapeutics Alternatives Peak Bio Alternatives Biodexa Pharmaceuticals Alternatives NexImmune Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TCBP) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TC Biopharm (Holdings) Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share TC Biopharm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
